News China Health Resource Issues Final Termsheet for Buyout of Herborium Jun 08, 2012 (Close-Up Media via COMTEX) -- China Health Resource, Inc., announced it has issued a final termsheet to Herborium Group and is now awaiting response from the Herborium Board of Directors.
According to a release on June 5, Steve Weiss, USA Director of Strategic Acquisitions and Financial Marketing stated, "I am most excited to have united and introduced both CHRI with HBRM and my hope is for a favorable outcome. As CHRI revenues continue to significantly break all time new highs in their TCM products in China it is my hope that these products will be introduced to all natural western markets with new domestic distribution channels."
"We are proceeding with our Go Global Initiative which includes setting-up headquarter operations in the USA and expansion into other key regions like Latin America and Africa where we find opportunities to grow our business," says Jiayin Wang, CEO of CHRI.
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is a the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.